Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CBAY
- Price
- -
- Stock movement up
- +- (%)
- Company name
- Cymabay Therapeu
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 3.73B
- Ent value
- 3.66B
- Price/Sales
- 119.98
- Price/Book
- 12.76
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -4.58%
- 1 year return
- 269.51%
- 3 year return
- 86.46%
- 5 year return
- 20.25%
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
CBAY does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 119.98 |
| Price to Book | 12.76 |
| EV to Sales | 117.92 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 114.78M |
| EPS (TTM) | -0.99 |
| FCF per share (TTM) | -0.64 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 31.07M |
| Gross profit (TTM) | 30.39M |
| Operating income (TTM) | -101.68M |
| Net income (TTM) | -111.68M |
| EPS (TTM) | -0.99 |
| EPS (1y forward) | -1.05 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 97.81% |
| Operating margin (TTM) | -327.23% |
| Profit margin (TTM) | -359.40% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 206.53M |
| Net receivables | 0.00 |
| Total current assets | 403.80M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 9.15M |
| Total assets | 434.69M |
| Accounts payable | 3.83M |
| Short/Current long term debt | 114.49M |
| Total current liabilities | 36.84M |
| Total liabilities | 142.43M |
| Shareholder's equity | 292.26M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -72.53M |
| Capital expenditures (TTM) | 445.00K |
| Free cash flow (TTM) | -72.98M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -38.21% |
| Return on Assets | -25.69% |
| Return on Invested Capital | -27.82% |
| Cash Return on Invested Capital | -18.18% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| CBAY | S&P500 | |
| Current price drop from All-time high | -0.03% | - |
| Highest price drop | -92.85% | -56.47% |
| Date of highest drop | 11 Feb 2016 | 9 Mar 2009 |
| Avg drop from high | -54.62% | -11.07% |
| Avg time to new high | 42 days | 12 days |
| Max time to new high | 1389 days | 1805 days |
COMPANY DETAILS
Marketcap
3.73B
Marketcap category
Mid-cap
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California. As of March 22, 2024, CymaBay Therapeutics, Inc. operates as a subsidiary of Gilead Sciences, Inc.
Employees
101
Website
Investor relations
-
SEC filings
CEO
Sujal Shah
Country
USA
City
Newark
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner